Table 2.

The major pharmacokinetic parameters of aripiprazole and dehydroaripiprazole in CYP2D6 EMs and IMs with and without paroxetine (PRX)

CYP2D6 genotype	Aripiprazole						Dehydroaripiprazole
	EM (n = 7)			IM (n = 7)			EM (n = 7)			IM (n = 7)
Dose	APZ alone	APZ + PRX	Ratio/difference	APZ alone	APZ + PRX	Ratio/difference	APZ alone	APZ + PRX	Ratio/difference	APZ alone	APZ + PRX	Ratio/difference
Cmax (ng/mL)	12.6 ± 2.6	17.7 ± 4.6	1.39a	14.5 ± 3.4	18.1 ± 3.0	1.27a	1.3 ± 0.3	0.9 ± 0.1	0.67	1.0 ± 0.2	0.8 ± 0.1	0.88
\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ {\text{AU}}{{\text{C}}_{\infty }} $$\end{document} (ng·h/mL)	582 ± 150	1,374 ± 211	2.40a	1,316 ± 209	1,703 ± 192	1.30a	244 ± 39	295 ± 49c	1.21	328 ± 62d	289e	0.89
tmax (h)	3.3 ± 1.7	1.7 ± 0.5	−1.57b	3.3 ± 1.6	2.3 ± 1.0	−1.00	51.4 ± 16.6	89.1 ± 38.5	37.71	103.0 ± 38.7	133.7 ± 27.2	30.71
t1/2,z (h)	60.7 ± 9.2	111.0 ± 15.7	1.83a	106.6 ± 18.9	129.0 ± 21.3	1.21a	86.1 ± 10.7	165.3 ± 27.4c	1.91	181.4 ± 77.4d	123.2e	0.73
CL/F (L/h)	5.42 ± 1.25	2.22 ± 0.31	0.42a	2.32 ± 0.33	1.78 ± 0.20	0.77a

Values are mean ± standard deviation

EM Extensive metabolizer, IM intermediate metabolizer

^aRatio (period II/period I)

^bDifference (period II − period I)

^c n = 5, ^d n = 4, ^e n = 1 (number of subjects with available data for pharmacokinetic analysis)